Case report: Deciphering the clinical significance of a novel partial BRCA1 exon 10 duplication in a patient with triple-negative breast cancer

Pathogenic/likely pathogenic germline variants in the <i>BRCA1</i> and <i>BRCA2</i> genes are associated with an increased risk of developing cancer, particularly breast and/or ovarian tumors. The identification and correct classification of these variants is crucial to find individuals with an increased risk of cancer and to support physicians in their clinical and therapeutic decisions. In addition, the status of <i>BRCA1</i> and <i>BRCA2</i> variants is important for appropriate management of patients' family members. Here, we describe the case of a woman who developed triple-negative breast cancer at the age of 49 years. NGS analysis of <i>BRCA1</i> and <i>BRCA2</i> genes revealed the presence of a new partial <i>BRCA1</i> exon 10 duplication of 2.012 bp. The identified duplication comprises 395 nucleotides from the final portion of intron 9 and 1617 nucleotides from the beginning of exon 10. Using specific primers, we were able to identify the breakpoint at the DNA level and characterize the alteration as a tandem duplication leading to the formation of a premature stop codon after 10 residues. RNA analysis allowed to confirm the production of an altered mRNA showing the duplicated sequence. In this way, we were able to assign a clinical significance to the new alteration and classify it as a pathogenic variant. Although new ClinGen ENIGMA guidelines have been produced to provide tools for the accurate interpretation of variants in the <i>BRCA1</i> and <i>BRCA2</i> genes, defining the clinical significance of copy number variants, particularly duplications, remains a challenging goal that requires complex approaches to accurately determine the role of such variants. Other investigations, such as the detection of breakpoints by RNA analysis, are often essential to classify the identified alteration. Our study suggests that RNA transcript analysis is an ideal methodology to support the accurate classification of variants and clarify their effects.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2025-02-06
DOI
https://doi.org/10.3389/fonc.2025.1497531
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Case report: Deciphering the clinical significance of a novel partial BRCA1 exon 10 duplication in a patient with triple-negative breast cancer

Dariane Jornada Clerici, Davide Sacco, Lucy Costantino, Luigi Corsaro et al.
Frontiers in Oncology
BRCA gene mutations in cancer
article

Case report: Deciphering the clinical significance of a novel partial BRCA1 exon 10 duplication in a patient with triple-negative breast cancer

Dariane Jornada Clerici, Davide Sacco, Lucy Costantino, Luigi Corsaro, Carlo Santaniello, Alice Faversani, Giulia Melloni, Laura Gargiulo, F. Ferrara, Davide Barteselli, Debora Manuelli
article en

Abstract

Pathogenic/likely pathogenic germline variants in the <i>BRCA1</i> and <i>BRCA2</i> genes are associated with an increased risk of developing cancer, particularly breast and/or ovarian tumors. The identification and correct classification of these variants is crucial to find individuals with an increased risk of cancer and to support physicians in their clinical and therapeutic decisions. In addition, the status of <i>BRCA1</i> and <i>BRCA2</i> variants is important for appropriate management of patients' family members. Here, we describe the case of a woman who developed triple-negative breast cancer at the age of 49 years. NGS analysis of <i>BRCA1</i> and <i>BRCA2</i> genes revealed the presence of a new partial <i>BRCA1</i> exon 10 duplication of 2.012 bp. The identified duplication comprises 395 nucleotides from the final portion of intron 9 and 1617 nucleotides from the beginning of exon 10. Using specific primers, we were able to identify the breakpoint at the DNA level and characterize the alteration as a tandem duplication leading to the formation of a premature stop codon after 10 residues. RNA analysis allowed to confirm the production of an altered mRNA showing the duplicated sequence. In this way, we were able to assign a clinical significance to the new alteration and classify it as a pathogenic variant. Although new ClinGen ENIGMA guidelines have been produced to provide tools for the accurate interpretation of variants in the <i>BRCA1</i> and <i>BRCA2</i> genes, defining the clinical significance of copy number variants, particularly duplications, remains a challenging goal that requires complex approaches to accurately determine the role of such variants. Other investigations, such as the detection of breakpoints by RNA analysis, are often essential to classify the identified alteration. Our study suggests that RNA transcript analysis is an ideal methodology to support the accurate classification of variants and clarify their effects.

Frontiers in OncologyVol. 15
University of Pavia (IT), Centro Diagnostico Italiano (IT)
Openalex Percentile: Top 97%
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.